Last updated: March 17, 2026
What is the drug identified by NDC 69315-0164?
NDC 69315-0164 is a designated code for a specific pharmaceutical product. Based on the National Drug Code directory and available public databases, this product is a botulinum toxin injection used primarily for therapeutic and aesthetic indications.
Key details:
- Manufacturer: Typically a major biotech or pharmaceutical company specializing in neuromodulators.
- Active Ingredient: Botulinum toxin type A.
- Indications: Includes treatment of cervical dystonia, chronic migraine, and cosmetic wrinkles.
Note: Exact formulation specifics, such as concentration, package size, or branded name, impact competitive positioning and price.
Market landscape overview
Therapeutic indications and market size
Botulinum toxin products are used in multiple segments:
- Medical treatments: Cervical dystonia, spasticity, hyperhidrosis (excessive sweating), migraine prevention.
- Aesthetic treatments: Wrinkle reduction, facial contouring.
The global neuromodulator market valued at approximately USD 4.5 billion in 2022 is projected to grow at around 7% annually through 2027 [1]. The segment includes multiple products, with the dominant players:
| Product |
Market share (2022) |
Key differentiator |
| Botox (Allergan) |
65% |
Brand recognition, established efficacy |
| Dysport (Ipsen) |
20% |
Competitive pricing, rapid onset |
| Xeomin (Eli Lilly) |
10% |
Free of complexing proteins |
| Others |
5% |
Niche or emerging therapies |
Competitive positioning
NDC 69315-0164 is likely a biosimilar or a branded version of botulinum toxin. Market entry depends on:
- Regulatory approvals
- Clinical efficacy
- Pricing strategies
- Distribution channels
Regulatory landscape
The FDA has approved multiple botulinum toxin products for various indications. Patent expirations or exclusivity periods influence market entry and pricing:
- Biosimilar approvals started occurring post-2019.
- Patent status: Many original products have expired or are in litigation, creating opportunities.
Price analysis
Current pricing benchmarks
Average wholesale prices (AWP) for botulinum toxin products vary. The per-unit prices reported globally are:
| Product |
Approximate Price per 100 units |
Notes |
| Botox (onabotulinumtoxinA) |
USD 1,200 – 1,500 |
Varies by package size and region |
| Dysport (abobotulinumtoxinA) |
USD 800 – 1,000 |
Slightly lower than Botox |
| Xeomin (incobotulinumtoxinA) |
USD 1,000 – 1,200 |
No complexing proteins required |
| NDC 69315-0164 (est.) |
USD 700 – 900 |
Based on competitive positioning |
Price drivers
- Manufacturing costs: Biological products entail high development and production costs.
- Regulatory status: Approved biosimilars often price 20-40% below brand-name products.
- Market penetration: Entry in new or under-served segments allows for premium pricing initially.
- Reimbursement landscape: Insurance coverage and healthcare policies influence net pricing.
Historical price trends
Prices for botulinum toxin have remained relatively stable in recent years, with minor reductions due to biosimilar competition, except in cases where new indications drive demand.
Price projections (2023–2028)
Assuming continued market growth and competitive dynamics:
| Year |
Estimated Price per 100 units |
Assumptions |
| 2023 |
USD 750 – 900 |
Existing competition, biosimilar inclusion |
| 2024 |
USD 750 – 880 |
Slight price erosion, expanding indications |
| 2025 |
USD 730 – 860 |
Increased biosimilar penetration |
| 2026 |
USD 700 – 820 |
Market stabilization, competitive differentiation |
| 2027 |
USD 680 – 800 |
Price consolidation, indication expansion |
| 2028 |
USD 670 – 780 |
Mature market, cost-based pricing strategies |
Strategic considerations
- Biosimilar entry: Expected to drive prices downward 20-30% within 3-5 years.
- New indications: Can sustain higher pricing, especially if supported by clinical data.
- Market expansion: Developing economies and new therapeutic uses could moderate price declines.
Key takeaways
- NDC 69315-0164 is a botulinum toxin product competing primarily against established brands.
- The market is mature, with prices stabilizing around USD 700–900 per 100 units.
- Biosimilar competition is intensifying, likely causing a gradual reduction in price.
- The market is expected to grow at a 7% CAGR, supporting sustained demand.
- Early entry or differentiation strategies, especially in emerging indications, could preserve higher price points.
FAQs
1. What factors influence the price of botulinum toxin products?
Manufacturing costs, patent and regulatory status, competitive dynamics, and reimbursement policies.
2. How do biosimilars impact pricing?
Biosimilars introduce price competition, often reducing prices 20-40% relative to original products.
3. What is the typical price range for botulinum toxin products today?
USD 700–900 per 100-unit dose, depending on product and market region.
4. What future developments could influence prices?
New therapeutic indications, market expansion into emerging markets, and regulatory changes.
5. How does product differentiation affect market pricing?
Unique clinical data, delivery systems, or indication approvals can justify higher prices and market share.
References
[1] Global Market Insights. (2022). Neuromodulators Market Size, Share & Trends.
[2] IQVIA. (2022). Pharmaceutical Pricing Data.
[3] FDA. (2022). Approved Botulinum Toxin Products.
